Literature DB >> 34409600

Association of prescription drug monitoring program laws with bedridden and missed work days.

Martha Wetzel1, Courtney R Yarbrough1, Silke A von Esenwein2, Jason M Hockenberry3.   

Abstract

OBJECTIVE: To examine the relationship between optional and must-use prescription drug monitoring programs (PDMPs) and markers of disability. DATA SOURCES: Nationwide data from the National Health Interview Survey for 2006-2015. STUDY
DESIGN: Generalized difference-in-difference models with state-specific time trends were used to assess the relationship between PDMPs and two outcomes: missed days of work and bedridden days. DATA COLLECTION/EXTRACTION
METHODS: All respondents above the age of 18 years with complete data on key measures were included. A subpopulation of respondents who had a recent surgery or injury was identified. PRINCIPAL
FINDINGS: We found an increase of 3.3 and 5.9 bedridden days associated with optional and must-use PDMPs, respectively, for respondents reporting a recent injury or surgery (p-values <0.05; unadjusted population average 12.2 bedridden days). Increases in days of missed work were not statistically significant.
CONCLUSIONS: Implementation of PDMPs was associated with negative unintended consequences in the injury/surgery subpopulation. The association between bedridden days and PDMPs suggests a gap between clinical trials showing equivalence of opioids and nonopioids for pain treatment and real-world results. As increasingly tighter opioid restrictions proliferate, evidence-based strategies to address pain without opioids in the acute pain population likely need to be more widely disseminated.
© 2021 Health Research and Educational Trust.

Entities:  

Keywords:  acute pain; analgesics; opioid; pain management; prescription drug monitoring programs; state health policies

Mesh:

Substances:

Year:  2021        PMID: 34409600      PMCID: PMC8586471          DOI: 10.1111/1475-6773.13705

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  32 in total

1.  Prevalence and characteristics of opioid use in the US adult population.

Authors:  Judith Parsells Kelly; Suzanne F Cook; David W Kaufman; Theresa Anderson; Lynn Rosenberg; Allen A Mitchell
Journal:  Pain       Date:  2008-03-14       Impact factor: 6.961

2.  Prescription Drug Monitoring Programs Produce a Limited Impact on Painkiller Prescribing in Medicare Part D.

Authors:  Courtney R Yarbrough
Journal:  Health Serv Res       Date:  2017-01-18       Impact factor: 3.402

3.  Mandatory use of prescription drug monitoring programs.

Authors:  Rebecca L Haffajee; Anupam B Jena; Scott G Weiner
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

4.  Deaths: Final Data for 2015.

Authors:  Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek; Sally C Curtin; Elizabeth Arias
Journal:  Natl Vital Stat Rep       Date:  2017-11

5.  Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist.

Authors:  Ilana Graetz; Courtney R Yarbrough; Xin Hu; David H Howard
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

6.  Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-11-04       Impact factor: 17.586

7.  Opioid medication discontinuation and risk of adverse opioid-related health care events.

Authors:  Tami L Mark; William Parish
Journal:  J Subst Abuse Treat       Date:  2019-05-05

8.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

9.  Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.

Authors:  Patricia R Freeman; Geoffrey M Curran; Karen L Drummond; Bradley C Martin; Benjamin S Teeter; Katharine Bradley; Nancy Schoenberg; Mark J Edlund
Journal:  Res Social Adm Pharm       Date:  2018-09-14

Review 10.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more
  1 in total

1.  Association of prescription drug monitoring program laws with bedridden and missed work days.

Authors:  Martha Wetzel; Courtney R Yarbrough; Silke A von Esenwein; Jason M Hockenberry
Journal:  Health Serv Res       Date:  2021-08-19       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.